These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9340920)

  • 1. [Reducing cholesterol in cardiovascular rehabilitation--exercise versus drug therapy].
    Halle M; Berg A; Keul J
    Wien Klin Wochenschr; 1997; 109 Suppl 2():29-32. PubMed ID: 9340920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of smoking cessation, physical training and psychological interventions in secondary prevention of coronary heart disease].
    Jost S
    Z Kardiol; 1994 Oct; 83(10):742-58. PubMed ID: 7810188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins in secondary prevention of coronary heart disease].
    Sandhofer F
    Wien Med Wochenschr; 1999; 149(5-6):125-8. PubMed ID: 10408003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cholesterol abnormalities.
    Lockman AR; Tribastone AD; Knight KV; Franko JP
    Am Fam Physician; 2005 Mar; 71(6):1137-42. PubMed ID: 15791891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins-a panacea?].
    Klose G
    Z Kardiol; 2004; 93 Suppl 1():I19-22. PubMed ID: 15022003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease.
    Vestfold Heartcare Study Group
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):429-37. PubMed ID: 14671465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of Hong Kong Chinese patients with coronary heart disease.
    Chair SY; Lee SF; Lopez V; Ling EM
    J Clin Nurs; 2007 Jul; 16(7):1278-84. PubMed ID: 17584346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence of the efficacy of hypocholesterolemic treatment in primary and secondary prevention of ischemic heart disease].
    Alvarez-Sala Walther LA; Millán Núñez-Cortés J
    Med Clin (Barc); 2000; 114 Suppl 2():1-10. PubMed ID: 10916798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an expanded cardiac rehabilitation programme in patients treated for an acute myocardial infarction or a coronary artery by-pass graft operation.
    Plüss CE; Karlsson MR; Wallen N; Billing E; Held C
    Clin Rehabil; 2008 Apr; 22(4):306-18. PubMed ID: 18390974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical risk factors and emerging elements in the risk profile for coronary artery disease.
    Gensini GF; Comeglio M; Colella A
    Eur Heart J; 1998 Feb; 19 Suppl A():A53-61. PubMed ID: 9519344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention of coronary heart disease in elderly patients.
    Hanna IR; Wenger NK
    Am Fam Physician; 2005 Jun; 71(12):2289-96. PubMed ID: 15999866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term secondary prevention programs after cardiac rehabilitation for the reduction of future cardiovascular events: focus on regular physical activity.
    Scrutinio D; Temporelli PL; Passantino A; Giannuzzi P
    Future Cardiol; 2009 May; 5(3):297-314. PubMed ID: 19450055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.